Form 4: Sangamo Therapeutics Executive Sells Shares to Cover Tax Obligations After RSU Vesting

A Sangamo Therapeutics executive, Scott B. Willoughby, sold shares to cover tax obligations following the vesting of restricted stock units.

Summary

• Scott B. Willoughby, a Senior Vice President at Sangamo Therapeutics, sold shares of common stock to cover tax obligations related to the vesting of restricted stock units (RSUs).
• On November 24, 2024, 1,430 shares were sold at $1.88 per share to cover taxes from a vesting event.
• On November 25, 2024, 1,371 shares were sold at $1.94 per share for the same purpose.
• These sales were not discretionary trades but were required for tax withholding purposes.
• The executive still holds a significant number of shares, including those from previous RSU grants that will vest over time.

Sentiment

Score: 6

Explanation: The document reflects a routine transaction for tax purposes, not a significant change in the executive's view of the company. The sentiment is neutral to slightly positive due to the continued vesting of RSUs.

Positives

• The executive's remaining holdings include a substantial number of shares from multiple RSU grants, indicating continued alignment with the company's success.
• The vesting schedule of the RSU grants provides a long-term incentive for the executive.

Negatives

• The sales of shares, while for tax purposes, may be perceived negatively by some investors.

Risks

• The stock price could be affected by future sales of shares by executives, even if for tax purposes.
• Changes in tax laws could impact the amount of shares needed to be sold for tax obligations.

Future Outlook

The executive's remaining RSU grants will continue to vest over time, subject to continued service.

Management Comments

• The sales were solely for mandatory tax withholding purposes and do not represent discretionary trades by the Reporting Person.

Industry Context

This type of transaction is common for executives who receive equity compensation, as they often need to sell shares to cover taxes when RSUs vest.

Comparison to Industry Standards

• Similar transactions are regularly seen across the biotechnology industry, where equity compensation is a significant part of executive pay.
• Companies like Gilead Sciences and Biogen also use RSU grants as part of their compensation packages, and their executives often report similar sales for tax purposes.
• The vesting schedules and tax withholding practices are generally consistent with industry norms.

Stakeholder Impact

• Shareholders may view the sales as a slight negative, but they are routine and not indicative of a lack of confidence in the company.
• Employees may see this as a normal part of equity compensation.

Next Steps

• The executive's remaining RSU grants will continue to vest over time, subject to continued service.

Key Dates

Keywords

Sangamo Therapeutics, RSU, stock sale, executive, tax withholding, equity compensation, insider trading, SEC Form 4